Evidence map›Paper›PMID 37386033›Full record

ArticleNPJ Parkinson's disease2023

Predictive value of abbreviated olfactory tests in prodromal Parkinson disease.

Pavan A Vaswani, James F Morley, Danna Jennings, Andrew Siderowf, Kenneth Marek, PARS Investigators

Abstract read
In one paragraph

Article in NPJ Parkinson's disease, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Pavan A VaswaniParkinson's Disease Research, Education and Clinical Center, Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA, USA. pavan.vaswani@pennmedicine.upenn.edu.ORCID http://orcid.org/0000-0002-1826-6275
James F MorleyParkinson's Disease Research, Education and Clinical Center, Corporal Michael J. Crescenz VA Medical Center, Philadelphia, PA, USA.
Danna JenningsThe Institute for Neurodegenerative Disorders, New Haven, CT, USA.
Andrew SiderowfDepartment of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.ORCID http://orcid.org/0000-0002-1750-7698
Kenneth MarekThe Institute for Neurodegenerative Disorders, New Haven, CT, USA.
PARS Investigators

Funding

Dissecting Oligogenic Biomarkers in Ashkenazi Jews with Parkinson DiseaseU01NS107016 · NINDS · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI OZELIUS, LAURIE J., SAUNDERS-PULLMAN, RACHEL · 2019 to 2023
$6.6M
NINDS NIH HHS U01 NS107016U.S. Department of Defense (United States Department of Defense) W81XWH-06-067
6 · The paper itself

Abstract

There is disagreement in the literature whether olfaction may show specific impairments in Parkinson Disease (PD) and if olfactory tests comprised of selected odors could be more specific for diagnosis. We sought to validate previously proposed subsets of the University of Pennsylvania Smell Identification Test (UPSIT) odors for predicting conversion to PD in an independent, prodromal cohort. Conversion to PD was assessed in 229 participants in the Parkinson At Risk Study who completed baseline olfactory testing with the UPSIT and up to 12 years of clinical and imaging evaluations. No commercially available or proposed subset performed better than the full 40-item UPSIT. The proposed "PD-specific" subsets also did not perform better than expected by chance. We did not find evidence for selective olfactory impairment in Parkinson disease. Shorter odor identification tests, including commercially available 10-12 item tests, may have utility for ease of use and cost, but not for superior predictive value.

Identifiers

PMID37386033
PMCPMC10310835

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.